Robust acute myeloid leukemia engraftment in humanized
scaffolds using injectable biomaterials and intravenous
xenotransplantation

J 2025

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation

BUŠA, Daniel; Zdeňka HERUDKOVÁ; Jan HÝL; Jakub VLAŽNÝ; Filip SOKOL et. al.

Basic information

Original name

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation

Authors

Edition

Molecular oncology, HOBOKEN, WILEY, 2025, 1574-7891

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 5.000 in 2023

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/1878-0261.13790

UT WoS

001401325000001

EID Scopus

999

Keywords in English

AML; collagen; mouse model; ossicles; patient-derived xenografts; T-cell

Abstract

V originále

Patient-derived xenografts (PDXs) can be improved by implantation of a humanized niche. Nevertheless, the overall complexity of the current protocols, as well as the use of specific biomaterials and procedures, limits the wider adoption of this approach. Here, we identify the essential minimum steps required to create the humanized scaffolds and achieve successful acute myeloid leukemia (AML) engraftment. We compared seven biomaterials, which included both published and custom-designed materials. The highest level of bone marrow niche was achieved with extracellular matrix gels and custom collagen fiber, both of which allowed for a simple non-surgical implantation. The biomaterial selection did not influence the following AML infiltration. Regarding xenotransplantation, standard intravenous administration produced the most robust engraftment, even for two out of four otherwise non-engrafting AML samples. In contrast, direct intra-scaffold xenotransplantation did not offer any advantage. In summary, we demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for AML xenotransplantation provide the most convenient and robust approach to produce AML PDX using a humanized niche.

Links

LX22NPO5102, research and development project

Name: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)

Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES

MUNI/A/1558/2023, interní kód MU

Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit XI

Investor: Masaryk University

Files attached

Robust_acute_myeloid_leukemia_engraftment_in_humanized_scaffolds_using_injectable_biomaterials_and_intravenous_xenotransplantation.pdf

Cite

BUŠA, Daniel; Zdeňka HERUDKOVÁ; Jan HÝL; Jakub VLAŽNÝ; Filip SOKOL; Květoslava MATULOVÁ; Adam FOLTA; Jakub HYNŠT; Lucy VOJTOVA; Leoš KŘEN; Martin REPKO; Zdeněk RÁČIL; Jiří MAYER and Martin ČULEN. Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation. Molecular oncology. HOBOKEN: WILEY, 2025, 15 pp. ISSN 1574-7891. Available from: https://dx.doi.org/10.1002/1878-0261.13790.

@article{2474621,
   author = {Buša, Daniel and Herudková, Zdeňka and Hýl, Jan and Vlažný, Jakub and Sokol, Filip and Matulová, Květoslava and Folta, Adam and Hynšt, Jakub and Vojtova, Lucy and Křen, Leoš and Repko, Martin and Ráčil, Zdeněk and Mayer, Jiří and Čulen, Martin},
   article_location = {HOBOKEN},
   doi = {http://dx.doi.org/10.1002/1878-0261.13790},
   keywords = {AML; collagen; mouse model; ossicles; patient-derived xenografts; T-cell},
   language = {eng},
   issn = {1574-7891},
   journal = {Molecular oncology},
   title = {Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation},
   url = {https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.13790},
   year = {2025}
}

TY  - JOUR
ID  - 2474621
AU  - Buša, Daniel - Herudková, Zdeňka - Hýl, Jan - Vlažný, Jakub - Sokol, Filip - Matulová, Květoslava - Folta, Adam - Hynšt, Jakub - Vojtova, Lucy - Křen, Leoš - Repko, Martin - Ráčil, Zdeněk - Mayer, Jiří - Čulen, Martin
PY  - 2025
TI  - Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation
JF  - Molecular oncology
PB  - WILEY
SN  - 15747891
KW  - AML
KW  - collagen
KW  - mouse model
KW  - ossicles
KW  - patient-derived xenografts
KW  - T-cell
UR  - https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.13790
N2  - Patient-derived xenografts (PDXs) can be improved by implantation of a humanized niche. Nevertheless, the overall complexity of the current protocols, as well as the use of specific biomaterials and procedures, limits the wider adoption of this approach. Here, we identify the essential minimum steps required to create the humanized scaffolds and achieve successful acute myeloid leukemia (AML) engraftment. We compared seven biomaterials, which included both published and custom-designed materials. The highest level of bone marrow niche was achieved with extracellular matrix gels and custom collagen fiber, both of which allowed for a simple non-surgical implantation. The biomaterial selection did not influence the following AML infiltration. Regarding xenotransplantation, standard intravenous administration produced the most robust engraftment, even for two out of four otherwise non-engrafting AML samples. In contrast, direct intra-scaffold xenotransplantation did not offer any advantage. In summary, we demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for AML xenotransplantation provide the most convenient and robust approach to produce AML PDX using a humanized niche.
ER  -

BUŠA, Daniel; Zdeňka HERUDKOVÁ; Jan HÝL; Jakub VLAŽNÝ; Filip SOKOL; Květoslava MATULOVÁ; Adam FOLTA; Jakub HYNŠT; Lucy VOJTOVA; Leoš KŘEN; Martin REPKO; Zdeněk RÁČIL; Jiří MAYER and Martin ČULEN. Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation. \textit{Molecular oncology}. HOBOKEN: WILEY, 2025, 15 pp. ISSN~1574-7891. Available from: https://dx.doi.org/10.1002/1878-0261.13790.

Přehled o publikaci